Description
Is Olarigen 150 mg right for your situation?
Review these criteria with your oncologist before enquiring- ✓BRCA1/2-mutated ovarian, fallopian tube, or primary peritoneal cancer, including maintenance after platinum chemotherapy
- ✓Germline BRCA-mutated, HER2-negative metastatic breast cancer previously treated with chemotherapy
- ✓BRCA1/2-mutated prostate or pancreatic cancer as determined by your oncologist
- ✓Need a WHO-GMP generic alternative to Lynparza® made by General Pharmaceuticals
- ✗No confirmed BRCA mutation or HRR gene alteration (genetic testing is mandatory before starting)
- ✗Pre-existing myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML)
- ✗Pregnant, planning pregnancy, or breastfeeding
- ✗Severe renal impairment without oncologist dose adjustment
Check Availability & Pricing
Prescription required · Named Patient Program · Worldwide shipping
🛡 WHO-GMP Certified · Prescription verified · Express dispatch
What is Olarigen 150 mg?
Olarigen 150 mg is a generic formulation of Olaparib — a first-in-class PARP (Poly ADP-ribose Polymerase) inhibitor — manufactured by General Pharmaceuticals Ltd. under cGMP compliant conditions in Bangladesh. Each tablet contains 150 mg of olaparib, the same active molecule found in Lynparza® (AstraZeneca), and is dispensed under the Named Patient Program for patients requiring a quality-assured, affordable alternative.
Olaparib targets tumour cells with homologous recombination repair (HRR) deficiency, most commonly caused by BRCA1 or BRCA2 mutations, using the principle of synthetic lethality.
| Generic name | Olaparib |
| Reference brand | Lynparza® (AstraZeneca) |
| Manufacturer | General Pharmaceuticals Ltd. |
| Standard | cGMP Compliant |
| Drug class | PARP Inhibitor |
| Dosage form | Tablet — 150 mg (also available 50 mg) |
| Pack size | 30 tablets per pack |
| Route | Oral · twice daily |
| Prescription | Required — oncologist only |
How Olaparib Works
Olarigen blocks PARP enzymes (PARP1, PARP2, and PARP3) in your cells. PARP plays a key role in repairing damaged DNA. Cancer cells with specific mutations, such as BRCA1 or BRCA2, already rely heavily on PARP to survive because their other DNA repair pathway is impaired.
What to Expect: First 30 Days
Olaparib is generally well tolerated for a maintenance therapy, though gastrointestinal symptoms and fatigue are common in the early weeks.
- Week 1: Nausea is common when starting therapy. Eating small, frequent, bland meals (like toast or crackers) and avoiding greasy or spicy foods can help significantly.
- Weeks 2–3: You may feel unusually tired — prioritise rest and try light activities like short walks to maintain energy levels. Blood work begins to be monitored closely during this window.
- Week 4: A baseline Complete Blood Count (CBC) and ongoing monthly CBC testing for the first year is essential to detect any drop in haemoglobin or white blood cells early.
Side Effects
Most side effects are manageable, but olaparib carries rare but serious risks that require ongoing monitoring throughout treatment.
Common · Usually Manageable
- Nausea and vomiting
- Fatigue
- Anaemia (low red blood cell count)
- Decreased appetite
- Diarrhoea
- Headache
- Altered taste
Serious · Report Immediately
- Myelodysplastic syndrome (MDS) / acute myeloid leukaemia (AML)
- Pneumonitis (lung inflammation)
- Severe or persistent low blood counts
- Venous thromboembolism (blood clots)
- New or worsening breathlessness, dry cough, or fever (possible pneumonitis)
- Unusual bruising, prolonged bleeding, or signs of infection (possible blood disorder)
- Sudden leg swelling/pain, chest pain, or breathlessness (possible blood clot)
How to Take Olarigen 150 mg
Standard dose: 300 mg (two 150 mg tablets) twice daily, for a total of 600 mg per day, with or without food.
- 1Two tablets, twice daily — approximately 12 hours apart, e.g. morning and evening.
- 2Swallow tablets whole with a glass of water. Do not chew, crush, or dissolve them.
- 3Avoid grapefruit and Seville oranges (including marmalade) — these significantly increase olaparib blood levels via CYP3A4 interaction.
- 4If you miss a dose, take your next dose at the scheduled time. Do not double up.
- 5Storage: below 30°C in a dry place, protected from sunlight, windows, or humid areas like bathrooms.
Caregiver Guidance
- ♥Track blood test appointments closely — a baseline CBC plus monthly testing for the first year is essential to catch low blood counts early.
- ♥Support nausea management — encourage small, frequent, bland meals and avoid greasy or spicy foods, especially in the first weeks.
- ♥Watch for fever or unusual bruising — report any signs of infection, unexplained bruising, or prolonged bleeding to the oncologist promptly.
If the Medicine Stops Working
Frequently Asked Questions
How does Olarigen 150 mg work against cancer?
Who manufactures Olarigen?
How should I store Olarigen tablets at home?
What monitoring is required while taking this medication?
Is Olarigen 150 mg the same as the 50 mg formulation?
How do I order Olarigen through Meds For Cancer?
Meds For Cancer operates as a Named Patient Program (NPP) facilitator. Under this framework, WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid oncologist prescription, in countries where the branded product is unavailable or unaffordable.
This service does not constitute retail pharmacy dispensing. A prescription review is mandatory before any order is processed.
- Moore K, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer (SOLO-1). NEJM 2018;379:2495–2505.
- Robson M, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation (OlympiAD). NEJM 2017;377:523–533.
- NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. V3.2026.
- de Bono J, et al. Olaparib for metastatic castration-resistant prostate cancer (PROfound). NEJM 2020;382:2091–2102.
Reviews
There are no reviews yet.